Even after a tumor has been removed and a patient is in remission, tiny traces of cancer can still remain in the bloodstream. Without knowing just how many of those cells remain, oncologists may under ...

Veracyte (Nasdaq: VCYT) announced it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual disease (MRD) detection ...

While many of the companies currently developing blood tests to help diagnose cancer or track the disease’s progression are churning out physical tests that can be sent out to labs and hospitals ...

Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe ...

If you or a loved one has ever undergone a tumor removal as part of cancer treatment, you’re likely familiar with the period of uncertainty and fear that follows. Will the cancer return, and if so, ...

C2i Genomics, a New York, NY-based cancer intelligence company, launched its C2inform minimal residual disease (MRD) test across Europe after snagging CE-IVD marking in the European Union, the United ...

Cancer intelligence company, C2i Genomics, will partner with with Karkinos Healthcare, a technology-led managed-care platform for cancer, to co-develop the MRD market in India. This partnership will ...